Geode Capital Management LLC Has $918,000 Stake in Coya Therapeutics, Inc. (NASDAQ:COYA)

Geode Capital Management LLC increased its position in Coya Therapeutics, Inc. (NASDAQ:COYA) by 3.3% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 142,309 shares of the company’s stock after purchasing an additional 4,485 shares during the period. Geode Capital Management LLC owned approximately 0.85% of Coya Therapeutics worth $918,000 at the end of the most recent quarter.

Separately, Renaissance Technologies LLC bought a new stake in Coya Therapeutics during the second quarter worth $101,000. Hedge funds and other institutional investors own 39.75% of the company’s stock.

Insider Buying and Selling

In other Coya Therapeutics news, CEO Arun Swaminathan acquired 5,000 shares of Coya Therapeutics stock in a transaction that occurred on Monday, November 11th. The stock was acquired at an average cost of $7.34 per share, for a total transaction of $36,700.00. Following the purchase, the chief executive officer now owns 5,000 shares of the company’s stock, valued at approximately $36,700. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In the last 90 days, insiders bought 9,510 shares of company stock valued at $69,615. 12.00% of the stock is owned by insiders.

Coya Therapeutics Price Performance

Shares of Coya Therapeutics stock opened at $5.77 on Friday. Coya Therapeutics, Inc. has a 1 year low of $4.75 and a 1 year high of $10.69. The stock has a fifty day moving average price of $6.16 and a 200-day moving average price of $6.50. The firm has a market cap of $96.40 million, a PE ratio of -8.88 and a beta of 0.46.

Coya Therapeutics (NASDAQ:COYA) last released its earnings results on Wednesday, November 6th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.15. As a group, equities analysts anticipate that Coya Therapeutics, Inc. will post -1.15 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have weighed in on COYA. D. Boral Capital reaffirmed a “buy” rating and set a $15.00 price objective on shares of Coya Therapeutics in a report on Wednesday, December 18th. HC Wainwright restated a “buy” rating and set a $18.00 price target on shares of Coya Therapeutics in a report on Monday, November 11th. Finally, Chardan Capital reiterated a “buy” rating and issued a $14.00 price objective on shares of Coya Therapeutics in a research note on Thursday, November 7th.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.